Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G1 phase cell cycle arrest

Oral Oncology

Volumn 45, Issue 2, 2009, Pages 109-115

  Yoshiba, Sayaka ^a   Ito, Daisuke ^a   Nagumo, Tatsuhito ^a   Shirota, Tatsuo ^a   Hatori, Masashi ^a   Shintani, Satoru ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

5 FU; Cell cycle; G1 phase; Hypoxia; Oral cancer; Resistance

Indexed keywords

FLUOROURACIL; GLYCOPROTEIN P; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P21; PROTEIN P27;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HYPOXIA; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; G1 PHASE; HUMANS; MOUTH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 58549084773     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.04.002     Document Type: Article

References (30)

1. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 6 (2004) 437-447
2. Song X., Liu X., Chi W., Liu Y., Wei L., Wang X., et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58 6 (2006) 776-784
3. Janssen H.L., Haustermans K.M., Balm A.J., and Begg A.C. Hypoxia in head and neck cancer: How much, how important?. Head Neck 27 7 (2005) 622-638
4. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev 13 2 (1994) 139-168
5. Brown J.M. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6 4 (2000) 157-162
6. Sakata K., Kwok T.T., Murphy B.J., Laderoute K.R., Gordon G.R., and Sutherland R.M. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 64 5 (1991) 809-814
7. Liang B.C. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 29 2 (1996) 149-155
8. Wartenberg M., Gronczynska S., Bekhite M.M., Saric T., Niedermeier W., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 113 2 (2005) 229-240
9. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62 12 (2002) 3387-3394
10. Sasabe E., Zhou X., Li D., Oku N., Yamamoto T., and Osaki T. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120 2 (2007) 268-277
11. Adamo V., Ferraro G., Pergolizzi S., Sergi C., Laudani A., Settineri N., et al. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol. 40 5 (2004) 525-531
12. Li M.H., Ito D., Sanada M., Odani T., Hatori M., Iwase M., et al. Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral Oncol 40 1 (2004) 63-70
13. Jin H.O., An S., Lee H.C., Woo S.H., Seo S.K., Choe T.B., et al. Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal 19 7 (2007) 1393-1403
14. Wartenberg M., Ling F.C., Muschen M., Klein F., Acker H., Gassmann M., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 17 3 (2003) 503-505
15. Comerford K.M., Cummins E.P., and Taylor C.T. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res 64 24 (2004) 9057-9061
16. Law B.K., Chytil A., Dumont N., Hamilton E.G., Waltner-Law M.E., Aakre M.E., et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 22 23 (2002) 8184-8198
17. Nourse J., Firpo E., Flanagan W.M., Coats S., Polyak K., Lee M.H., et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372 6506 (1994) 570-573
18. Fingar D.C., and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 18 (2004) 3151-3171
19. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., and Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94 2 (2006) 195-199
20. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5 8 (2006) 671-688
21. Easton J.B., and Houghton P.J. mTOR and cancer therapy. Oncogene 25 48 (2006) 6436-6446
22. Lee M., Hwang J.T., Yun H., Kim E.J., Kim M.J., Kim S.S., et al. Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma. Biochem Pharmacol 72 1 (2006) 91-103
23. Hamanaka Y., Mukai M., Shimamura M., Kitagawa T., Nishida T., Isohashi F., et al. Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia. Biochem Biophys Res Commun 330 1 (2005) 318-326
24. Sofer A., Lei K., Johannessen C.M., and Ellisen L.W. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 25 14 (2005) 5834-5845
25. Connolly E., Braunstein S., Formenti S., and Schneider R.J. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 26 10 (2006) 3955-3965
26. Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., and Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21 4 (2006) 521-531
27. Carling D. The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 29 1 (2004) 18-24
28. Li Y., Corradetti M.N., Inoki K., and Guan K.L. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 29 1 (2004) 32-38
29. Pan D., Dong J., Zhang Y., and Gao X. Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol 14 2 (2004) 78-85
30. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 5 (2003) 577-590